Enanta Pharmaceuticals, Inc. · NASDAQ:ENTA
Enanta Pharmaceuticals — Corporate Update (June 2026)
29 slides from Enanta Pharmaceuticals's corporate update, Jun 18, 2026
Slide 1: Zelicapavir Update
Zelicapavir Update June 18, 2026 1
Slide 2: Forward Looking Statements Disclaimer
Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which
Slide 3: Enanta Overview
Enanta Overview Clinical-stage All compounds biotechnology company discovered in dedicated to creating house, leveraging small molecule deep expertise in drugs for virology & medicinal chemistry, drug immunology indications discovery & development 2 products approved with Founded: 1995 STRONG CASH P
Slide 4: Enanta Pipeline
Enanta Pipeline DISEASE TARGET DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET Virology: Hepatitis C Virus Protease Glecaprevir* Liver Zelicapavir High-Risk Adults N-Protein Respiratory Zelicapavir Pediatrics Virology: Syncytial Virus Respiratory L-Protein EDP-323 (challenge study) COVID-19 3CL
Slide 5: RSV Treatment Opportunity Summary
Zelicapavir RSV Treatment Opportunity Summary • Enanta pioneering development with zelicapavir, a potential first-in-disease RSV treatment First-in-Disease Asset • First direct-acting therapeutic to demonstrate efficacy in adults at high risk for severe RSV • Resolved symptoms ~7 days faster and red
Slide 6: Respiratory Syncytial Virus: Disease Overview & Market Opportunity
Respiratory Syncytial Virus: Disease Overview & Market Opportunity 6
Slide 7: Respiratory Syncytial Virus (RSV)
Respiratory Syncytial Virus (RSV) Causes severe lung infections, including bronchiolitis (infection of small airways in the lungs) and pneumonia. No safe and effective treatments are currently approved. RSV Burden Estimates1 (2024 - 2025 U.S.) Significant Unmet Need for Antivirals • Adult vaccines h
Slide 8: Physicians Report High Unmet Need for RSV, Driven by Lack of Treatment
Physicians Report High Unmet Need for RSV, Driven by Lack of Treatment Inpatient Unmet Need Outpatient Unmet Need Average Unmet Need 1 7 (Average rating on a 7-point scale where 1= no 4.6 5.4 unmet need and 7= extremely high unmet need) Low High Unmet Need • Physicians desire an efficacious and indi
Slide 9: Epidemiology: RSV Infections in the US Adult Population
Epidemiology: RSV Infections in the US Adult Population At Least 1.2 Million “HR3” Adults at High Risk for Severe RSV Most prevalent and highest risk for hospitalization ~1.2M addressable high-risk “HR3” adult RSV outpatients Additional ~0.6M CKD and IC patients 1600 HR3 Type 2 Diabetes 1400 Asthma
Slide 10: Epidemiology: RSV Infections in the US Pediatric Population
Epidemiology: RSV Infections in the US Pediatric Population ~1.5 Million Pediatrics at High Risk for Severe RSV Despite RSV prophylaxis1: Hospitalizations still occur in eligible population (0-7 mo) ~1.5M at-risk addressable pediatric RSV outpatients Passive protection may shift events to subsequent
Slide 11: Rapid At-Home RSV Tests Now Widely Available
Rapid At-Home RSV Tests Now Widely Available: Increase RSV Diagnosis & Enable a Test-to-Treat Model Commercially available tests Combination Respiratory Viral Tests Now Available in major markets • Self-test for RSV, FluA/B and COVID (1st FDA approval in 2025) • Quick results ~15 mins, appropriate f
Slide 12: Payers Recognize High RSV Disease Burden and Unmet Need
Payers Recognize High RSV Disease Burden and Unmet Need, with Limited Management for Antivirals Zelicapavir Viewed Positively by Payers, Limited Pricing Pressure on Antivirals Addressing RSV Disease Burden • Declining payer focus on respiratory viral • Payers recognize high disease burden and infect
Slide 13: Multi-Billion Dollar Global Market Opportunity for an RSV Antiviral
Multi-Billion Dollar Global Market Opportunity for an RSV Antiviral Up to 4M Addressable Patients with RSV in the United States1 ~4M Additional High-Risk Adults: ~1.3M CKD, IC, T2DM, ONC Multi-Billion $ Global Revenue Potential2 ~$2.6B–3.5B HR3 Adults: • Additional High-Risk Adults ~1.2M CHF, COPD,
Slide 14: Zelicapavir: Clinical Overview & Development Path
Zelicapavir: Clinical Overview & Development Path 14
Slide 15: Zelicapavir (EDP-938): N-Protein Inhibitor for RSV
Zelicapavir (EDP-938): N-Protein Inhibitor for RSV • Only N-inhibitor in clinical development for RSV – Replication inhibitor: shuts down the production of new RSV virions (vs. fusion inhibitors which block viral entry) • Granted Fast Track designation by the FDA • Strong preclinical profile – Nanom
Slide 16: RSV Development Goal: Treatment for Patients at High-Risk for Severe RSV Infection
RSV Development Goal: Treatment for Patients at High-Risk for Severe RSV Infection Leading portfolio of RSV replication inhibitors with potential for first-in-disease (zelicapavir) and best-in-disease (EDP-323) treatments and ability for combination Age ≥65 years Zelicapavir High-Risk Adult Positive
Slide 17: Pediatric Program: First-in-Pediatric Phase Study Design
Zelicapavir Pediatric Program: First-in-Pediatric Phase 2 Study Design Primary Objective Double-Blind Inclusion Criteria Treatment Phase • Pediatric inpatients and outpatients with RSV Part 1: Overall: Antiviral activity Trial Design • Symptom onset within MAD vs Placebo 3 days of zelicapavir N=96 2
Slide 18: Pediatric Program: First-in-Pediatric Phase Study Summary
Zelicapavir Pediatric Program: First-in-Pediatric Phase 2 Study Summary • Well-tolerated, with favorable safety profile – No adverse events leading to treatment discontinuation or study withdrawal Primary Objectives of Study • Antiviral effect observed for the primary and secondary virology endpoint
Slide 19: Pediatric Program: Phase 2b Study Design
Zelicapavir Pediatric Program: Phase 2b Study Design Double-Blind Primary Objective Treatment Phase Randomized 1:1 Time to complete symptom Inclusion Criteria resolution as measured by Placebo (QD) RESOLVE-P Trial Design • Pediatric inpatients and outpatients with RSV 28 Day N=150 • Symptom onset wi
Slide 20: High-Risk Adult Program: Phase 2b Study Design
Zelicapavir High-Risk Adult Program: Phase 2b Study Design Inclusion Criteria Double-Blind Primary Objective Treatment Phase Time to resolution‡ of RSV LRTD • Adult outpatients with Randomized 2:1 RSV symptoms (RiiQ symptom scale) • Symptom onset within Shortness of breath, wheezing, Placebo (QD) Tr
Slide 21: Faster Time to Complete Symptom Resolution by RiiQ
Zelicapavir Phase 2b High-Risk Adult Study Faster Time to Complete Symptom Resolution by RiiQ Industry’s first proof-of-concept demonstrated in high-risk adult outpatients Efficacy Population HR3 Population* 7.2d 20 (34%) Median days to alleviation of symptoms Placebo 3.6d 6.7d 18 (35%) (19%) 16 Zel
Slide 22: Faster Time to Symptom Resolution by PGI-S
Zelicapavir Phase 2b High-Risk Adult Study Faster Time to Symptom Resolution by PGI-S • Statistically significant 2-day faster symptom resolution by PGI-S compared to placebo Efficacy Population (p=0.0446) HR3 Population (p=0.0465) Symptoms Being Unresolved Survival Probability of RSV Time Since Fir
Slide 23: Hospitalization and Death Endpoints
Zelicapavir Phase 2b High-Risk Adult Study Hospitalization and Death Endpoints • Lower hospitalization rate for patients treated with zelicapavir Placebo Zelicapavir All-cause hospitalizations 5.0% (3/60) 1.7% (2/115) RSV-associated hospitalizations 5.0% (3/60) 0% (0/115) (blinded investigator attri
Slide 24: Phase 2b High-Risk Adult Study Conclusions
Zelicapavir Phase 2b High-Risk Adult Study Conclusions • Zelicapavir demonstrated compelling results on multiple clinically meaningful & potential registrational endpoints measuring different aspects of RSV disease Up to one week improvement in complete RiiQ symptom resolution Statistically sign
Slide 25: Phase 2b/3 Study Elements
Zelicapavir Phase 2b/3 Study Elements Element Outcome Registrational Path Single Phase 2b/3 Study Primary endpoint Time to complete resolution of all 13 RSV symptoms as measured RiiQTM Study population Adult outpatients with CHF, COPD or 75 years or older (HR3) MITT of unvaccinated patients, vaccina
Slide 26: Phase 2b/3 Global Registrational Study Design
Zelicapavir High-Risk Adult (HR3) Program: Phase 2b/3 Global Registrational Study Design Double-Blind Primary Objective* Inclusion Criteria Treatment Phase • Adult outpatients with Randomization 1:1 Time to complete resolution of RSV* 13 RSV symptoms as measured by RiiQ • Symptom onset within 3 Plac
Slide 27: RSV Treatment Opportunity Summary
Zelicapavir RSV Treatment Opportunity Summary • Enanta pioneering development with zelicapavir, a potential first-in-disease RSV treatment First-in-Disease Asset • First direct-acting therapeutic to demonstrate efficacy in adults at high risk for severe RSV • Resolved symptoms ~7 days faster and red
Slide 28: Enanta RSV Portfolio Enables Sustained Leadership Position
Enanta RSV Portfolio Enables Sustained Leadership Position Designed to Address Broad Unmet Medical Needs First-in-Disease Best-in-Disease / Expansion Zelicapavir EDP-323 • Goal is to treat all high-risk patient populations (in/out-patients) – Pediatric patients (28 days – 3 years) – HR3 Adults: ≥75
Slide 29: www.enanta.com
Ei: Enanta Pharmaceuticals www.enanta.com
Enanta Pharmaceuticals — Corporate Update (June 2026) on 6ix